IgA Nephropathy Findings from SPARTAN and PROTECT Studies

Nephrology Times caught up with Chee Kay Cheung, PhD, MBChB, MRCP, at the 2024 National Kidney Foundation Spring Clinical Meetings. Dr. Cheung discussed two presentations on IgA nephropathy findings he was giving at the event: “Sparsentan (SPAR) as first-line treatment of incident patients with IgA nephropathy (IgAN): findings from the SPARTAN trial” and “Matching-adjusted indirect comparisons of eGFR slopes in the PROTECT study with UK RaDaR IgA nephropathy population and the control arm of NefIgArd.”